MarketResearchReports.Biz

Investigation Report on China Ranibizumab Market Trends and Forecast by 2019

 

Albany, NY -- (SBWIRE) -- 08/03/2015 -- Investigation Report on China Ranibizumab Market, 2012-2019 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.

Browse Complete Report with Toc: http://www.marketresearchreports.biz/analysis/302735

As macular is the area responsible for high-resolution vision near the center of the retina, macular degeneration, once occurred, will lead to a loss of central vision and distorted vision in the form of metamorphopsia or even irreversible blindness. According to a report published by WHO in 2012, 30 million people suffer from macular degeneration globally, among which about 500,000 end up in blindness per year. In the US, blindness cases caused by macular degeneration outnumbers those caused by glaucoma, cataract and diabetic retinopathy. According to a Chinese investigation in 2012, the incidence of macular degeneration reaches up to 15.5% among old people aged above 50 and 20.2% among those aged above 70. With ageing population, the incidence of macular degeneration will continue to go up.

Download The sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/302735

Developed by Novartis, ranibizumab was approved by CFDA to treat wet age-related macular degeneration (AMD) in 2012. Currently, only Lucentis, a product of Novartis, is available in the Chinese market. However, in Dec. 2013, as the first self-developed drug for the treatment of wet AMD in China, conbercept ophthalmic injection got CFDA's approval.

Ranibizumab develops fast after entering China, sales value in 19 sample hospitals in key cities in 2014 reaching CNY 245 million with a year-on-year growth of 26.29% and CAGR during the last three years reaching 200%. With ageing population, the incidence of macular degeneration goes up gradually. Hence the vast demand for ranibizumab in China. Currently, ranibizumab injections in mainland China all come from Novatis. But as conbercept ophthalmic injection is proved by the clinical studies to improve vision better with a lower administration frequency, it is expected to break the monopoly of Novatis in the wet AMD drug market in the next few years.

Browse More Reports Of Therapeutic Area Reports: http://www.marketresearchreports.biz/category/37

Readers can get at least the following information from this report:
market size of ranibizumab in China
competitive landscape of ranibizumab in Chinese market
price of ranibizumab made by different enterprises in China
market outlook of ranibizumab in China
The author suggests the following groups of people purchase this report:
manufacturers of monoclonal antibody
manufacturers of ophthalmic drugs
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service

About MarketResearchReports.biz
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

To View The Top Related News: http://www.marketresearchreports.biz/articles

Contact:
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: 518-621-2074
Website: http://www.marketresearchreports.biz/